The trial was designed to evaluate the effect in this population, over a period of up to five years, of a onceweekly subcutaneously administered dose of 2.4 mg semaglutide (Wegovy) on cardiovascular outcomes compared to placebo
The side effects of these weight-loss drugs include gastrointestinal symptoms such as nausea, diarrhoea, vomiting, constipation, reduced absorption of certain foods, heartburn, indigestion, fatigue, and dehydration
Initially developed for type 2 diabetes, these drugs are now widely used for obesity and cardiovascular risk reduction, with emerging applications in neurological disease [2, 3]
Our complete guide to grey-market peptides provides a comprehensive framework for navigating this space as safely as possible